Clinical Trial Search

Primary: Percentages of Subjects With N.Meningitidis Human Serum Bactericidal Activity (hSBA) Titers≥ 1:4, After One Dose of Either MenACWY-CRM Vaccine, With Adjuvant or Without…

Primary: Tumor Response Duration — 3.9; 24.1 months

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 - Main Phase — -22.9 Units on a scale

Primary: Accuracy in Judging Direction of Traffic at Traffic Intersection — 0 participants

Primary: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose of MK-2206 Administered Weekly in Combination With Weekly Paclitaxel 80 mg/m^2 and Trastuzumab 2 mg/m^2 — 135 mg

Primary: Change From Baseline on Clinical COPD Questionnaire (CCQ) Score — 1.8; 1.7; 1.7; 1.9 units on a scale

Primary: Percent Change From Baseline in Bone Mineral Density (BMD) of Axial Lumbar Spine — 1.53; 0.76; 0.47 Percentage increase from baseline — p=0.002

Primary: Percentage of Progression Free Participants After 16 Weeks of Treatment — 28.57; 0.00; 25.00 Percentage of participants

Primary: Average Number of Voids Per Day — NA; NA Average Number of Voids

Primary: Lens Front Surface Deposits at Day 7 — 1.53; 1.53 dichotomized grading scale

Primary: Number of Participants With Decline in GFR — 2; 2; 1; 4 participants

Primary: Percentage of Participants With Sustained Virologic Response at Follow-Up Week 24 (SVR24); — 41; 67; 96; 65 percentage of participants

Primary: Rate of Complete Dyspepsia Symptom Relief — 22.4; 29.3; 27.0; 17.9 Percentage of Participants

Primary: Progression-Free Survival (PFS) Time — 11.17; 6.90 Months. — p=0.0002

Primary: Change From Baseline in the Total Distance Walked During 6 Minute Walk Time (6MWT) at Week 12 — 17.42; 14.08; 14.08; 13.62 Meters — p=0.5802